The effect of levodopa on the blood antioxidant system and metabolome in patients with Parkinson's disease.

Q3 Biochemistry, Genetics and Molecular Biology

Biomeditsinskaya khimiya Pub Date : 2026-05-01 DOI:10.18097/PBMCR1642

D A Abaimov, T N Fedorova, A A Shabalina, A S Silantyev, D N Konanov, E Yu Fedotova, V V Poleshchuk, M N Andreev, O V Trifonova, D L Maslov, E E Balashova, D A Sychev, S N Illarioshkin, P G Lokhov

{"title":"The effect of levodopa on the blood antioxidant system and metabolome in patients with Parkinson's disease.","authors":"D A Abaimov, T N Fedorova, A A Shabalina, A S Silantyev, D N Konanov, E Yu Fedotova, V V Poleshchuk, M N Andreev, O V Trifonova, D L Maslov, E E Balashova, D A Sychev, S N Illarioshkin, P G Lokhov","doi":"10.18097/PBMCR1642","DOIUrl":null,"url":null,"abstract":"<p><p>The blood serum antioxidant status and the blood plasma metabolomic profile have been analyzed in Parkinson's disease (PD) patients, both pharmacologically naive and taking levodopa (treatment duration 7.4±5.4 years) at low (< 300 mg/day) and high (> 300 mg/day) doses. High-dose levodopa therapy caused changes in both the antioxidant status and metabolome of patients. High-dose levodopa treatment also activated lipid peroxidation, manifested by an increase in the level of lipid hydroperoxides. High-resolution mass spectrometry revealed accumulation of levodopa and dopamine metabolic products in the metabolome, particularly the neurotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), and associated changes in related metabolic pathways. Low-dose levodopa treatment did not cause significant changes in the antioxidant status and metabolome of patients, thus suggesting that maintaining a low-dose regimen as long as possible could potentially reduce neurotoxic metabolite accumulation and also maintain normal antioxidant functions in PD patients.</p>","PeriodicalId":8889,"journal":{"name":"Biomeditsinskaya khimiya","volume":"72 2","pages":"141-151"},"PeriodicalIF":0.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomeditsinskaya khimiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18097/PBMCR1642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

The blood serum antioxidant status and the blood plasma metabolomic profile have been analyzed in Parkinson's disease (PD) patients, both pharmacologically naive and taking levodopa (treatment duration 7.4±5.4 years) at low (< 300 mg/day) and high (> 300 mg/day) doses. High-dose levodopa therapy caused changes in both the antioxidant status and metabolome of patients. High-dose levodopa treatment also activated lipid peroxidation, manifested by an increase in the level of lipid hydroperoxides. High-resolution mass spectrometry revealed accumulation of levodopa and dopamine metabolic products in the metabolome, particularly the neurotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), and associated changes in related metabolic pathways. Low-dose levodopa treatment did not cause significant changes in the antioxidant status and metabolome of patients, thus suggesting that maintaining a low-dose regimen as long as possible could potentially reduce neurotoxic metabolite accumulation and also maintain normal antioxidant functions in PD patients.

查看原文本刊更多论文

左旋多巴对帕金森病患者血液抗氧化系统及代谢组的影响。

分析了帕金森病（PD）患者的血清抗氧化状态和血浆代谢组学特征，包括药理学上未接受治疗和服用左旋多巴（治疗持续时间7.4±5.4年）低剂量（< 300 mg/天）和高剂量（bb0 300 mg/天）的患者。大剂量左旋多巴治疗引起患者抗氧化状态和代谢组的改变。高剂量左旋多巴治疗也激活脂质过氧化，表现为脂质氢过氧化物水平的增加。高分辨率质谱分析揭示了代谢组中左旋多巴和多巴胺代谢产物的积累，特别是神经毒性多巴胺代谢物3,4-二羟基苯乙醛（DOPAL），以及相关代谢途径的相关变化。低剂量左旋多巴治疗并未引起患者抗氧化状态和代谢组的显著变化，提示尽可能长时间维持低剂量方案可能会减少PD患者神经毒性代谢物的积累，并维持正常的抗氧化功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomeditsinskaya khimiya Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The aim of the Russian-language journal "Biomeditsinskaya Khimiya" (Biomedical Chemistry) is to introduce the latest results obtained by scientists from Russia and other Republics of the Former Soviet Union. The Journal will cover all major areas of Biomedical chemistry, including neurochemistry, clinical chemistry, molecular biology of pathological processes, gene therapy, development of new drugs and their biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine etc. The Journal also publish review articles. All issues of journal usually contain invited reviews. Papers written in Russian contain abstract (in English).